Reduction mammaplasty is commonly performed for bilateral macromastia, congenital asymmetry, or as a contralateral symmetry procedure in breast reconstruction following mastectomy for cancer. Occult carcinoma has been detected in 0.06 percent to 0.4 percent of breast reduction specimens. The purpose of this study was to examine the incidence of breast cancer in breast reductions performed in one institution over a 14-year period. The authors reviewed their experience with 800 reduction mammaplasties performed between 1988 and 2001. Six cancers were detected (0.8 percent). Of these cancers, three were invasive (0.4 percent) and three were ductal carcinoma in situ (0.4 percent). Stratified by indication for surgery, there was a trend toward higher detection rates in the reconstruction group (1.2 percent) compared with the macromastia (0.7 percent) or congenital asymmetry (0 percent) groups. Mammography was performed preoperatively in these patients and all results were negative for masses or suspicious microcalcification. Pathological diagnosis was guided by gross specimen evaluation in two patients and specimen radiography in one patient. Reduction mammaplasty has a small but definite risk of finding cancer in the resection specimen. (Plast. Reconstr. Surg. 113:
Reduction mammaplasty ranks among the top five reconstructive surgical procedures performed by plastic surgeons in the United States. 1 The primary indication is macromastia, a proliferation of breast tissue leading to distorted perceptions of weight and breast size. 2 The pendulous breasts cause shoulder and back discomfort and hinder physical exercise. Surgical reduction relieves pain and facilitates a more active lifestyle. Major complications are rare and patients, overall, are very satisfied.
Maliniac first described the association of breast cancer and reduction mammaplasty, incriminating his free nipple graft as the source of ductal stasis and subsequent carcinoma. 3 This stimulated a series of case reports and three large surveys to further delineate the role of reduction mammaplasty in carcinogenesis. [3] [4] [5] [6] [7] [8] [9] In a survey of 250 plastic surgeons, Snyderman and Lizardo 7 reported cancer detection in 0.4 percent (confidence interval, 0.24 to 0.62 percent) of 5008 reduction specimens. Jansen et al. 8 repeated a similar survey 40 years later in New Orleans and found an incidence of 0.16 percent (confidence interval, 0.04 to 0.40 percent) of 2576. More recently, Tang et al. 9 documented invasive carcinoma in 0.06 percent (confidence interval, 0.03 to 0.09 percent) of 27,500 breast reductions from the Ontario registry.
These surveys report a range in the incidence of cancer detection in the reduction mammaplasty patient with no overlap in confidence intervals between the first two surveys and Tang's large cohort. The differences could be attributed to several factors. Snyderman and Lizardo 7 included patients with cancer detection in the preoperative work-up, which would increase the incidence. The lower incidence reported by Tang et al. 9 may be in part because they only focused on invasive cancers and did not include ductal carcinoma in situ, a malignant lesion of the breast treated as a cancer. 10 There may also have been differences in pathological processing of specimens and the patient populations may have been different, as the first two surveys were local questionnaires and the third survey based on a large registry.
We report on the incidence of cancer detection in reduction mammaplasty specimens from one institution over a 14-year period. We include intraoperative and postoperative diagnosis of invasive carcinoma or ductal carcinoma in situ. One pathology department has processed all specimens. Furthermore, we hypothesize the incidence may vary according to indication for surgery and the data are stratified accordingly.
METHODS
Institutional review board approval was obtained for chart review. The plastic surgery database was searched for bilateral or unilateral reduction mammaplasty specimens from 1988 to 2001. This was cross-referenced with the pathology database for diagnoses of carcinoma or carcinoma in situ. Confidence intervals were based on Poisson distribution. All pathology specimens were thinly sectioned. At least two blocks were examined histologically per breast plus any grossly abnormal tissue.
RESULTS
A total of 800 reduction mammaplasty procedures (611 bilateral and 189 unilateral) were performed from 1988 to 2001. These procedures are divided into three groups according to indications for surgery: macromastia (611 bilateral), congenital asymmetry in patients without known cancer (19 unilateral), and contralateral reduction performed to improve reconstruction symmetry in patients with known cancer (170 unilateral) ( Table I) . Combining all groups, cancer was detected in six specimens (0.8 percent; confidence interval, 0.28 to 1.63 percent). Of these six, three were invasive cancer (0.4 percent) and three were ductal carcinoma in situ (0.4 percent). Of note, four additional specimens contained a risk marker for breast cancer, lobular carcinoma in situ. In the macromastia group (611 patients), invasive cancer was detected in 0.3 percent and ductal carcinoma in situ in 0.3 percent for a total cancer detection rate of 0.7 percent (four of 611; confidence interval, 0.18 to 1.68 percent).
No cancer was detected in the congenital asymmetry group. In the reconstruction group, invasive cancer was detected in 0.6 percent and ductal carcinoma in situ in 0.6 percent for a total detection rate of 1.2 percent (confidence interval, 0.14 to 4.20 percent).
Characteristics of the individual patients with cancer are listed in Table II . The combined average age of our patients was 46 years. It was lower in the macromastia group (38 years) than the reconstruction group (61 years). All patients had preoperative mammography; no suspicious masses or microcalcifications were detected. There were no suspicious findings intraoperatively. One patient (patient 1) had specimen radiography. This revealed microcalcifications and directed pathological examination. Routine gross evaluation with thin slicing through the specimen revealed a suspicious lesion in two specimens (patients 2 and 3). All final diagnoses were made by histopathological review of the slides. Pathological characteristics of the invasive cancers are listed in Table II .
Treatment involved a combination of mastectomy, axillary lymph node dissection, chemotherapy, and radiation for patients with invasive carcinomas and one patient with ductal carcinoma in situ (Table II) . One patient was referred to a general surgeon to discuss treatment options, but she never kept the appointment and she was lost to follow-up. Observational treatment was advised for one small ductal carcinoma in situ lesion thought to be completely excised and all lobular carcinoma in situ patients.
DISCUSSION
One in eight women in the United States will develop breast cancer in their lifetime, and the incidence continues to increase. 11 The number of reduction mammaplasty procedures has increased by more than 150 percent in 10 years, reaching almost 100,000 in 2000. 1 It should thus come as no surprise that an occasional cancer is detected in seemingly normal breast reduction specimens. The literature reports an incidence of cancer detection between 0.06 percent and 0.4 percent. [7] [8] [9] With the incidence of cancer so infrequent, large studies have been based upon regional surveys. The detection of invasive carcinoma in our series is at the higher end of the incidence range reported and with the addition of ductal carcinoma in situ, the total incidence is even higher at 0.8 percent. Our study is limited by small sample size, and our results do not lie outside the confidence intervals for the surveys of Snyderman and Lizardo 7 and Jansen et al. 8 Our series may be different from others in including ductal carcinoma in situ, a malignant lesion of the breast treated with surgical excision. 10 This is in contrast to lobular carcinoma in situ, a bystander lesion serving as a risk marker for future malignancy in either breast. Patients with lobular carcinoma in situ are treated with observation and are not included in our incidence of cancer detection. 10 Moreover, 21 percent of our reduction mammaplasty specimens were from a unilateral procedure for reconstruction in patients with known carcinoma. This group is at higher risk for cancer than the general population. 11 Furthermore, as this is a retrospective study, we cannot rule out bias by our pathologists to examine tissue more closely in this group of patients with known carcinoma. If we separate our data into patient groups receiving surgery for macromastia, congenital asymmetry, or reconstruction, we note a trend toward higher detection of cancer in the reconstruction group (1.2 percent) compared with the macromastia (0.7 percent) or congenital asymmetry (0 percent) groups. The difference is even greater if the macromastia risk is divided by two for cancer risk per breast (1.2 percent for reconstruction versus 0.3 percent for macromastia). This could be important for counseling patients preoperatively and larger prospective studies are needed to more definitively address this issue and define the true incidence of cancer in each group.
Two generalizations can be derived from the Ontario population-based series of breast cancer detected in reduction mammaplasty patients: the women are younger at diagnosis (average age, 49 years) and have increased 5-year survival compared with the general population with breast cancer (88 percent versus 77 percent), suggesting detection of cancer at an earlier stage, when it is easier to treat. 9 In accordance, the average age of our patients is 46 years, and it is even younger in those undergoing reduction surgery for macromastia (38 years). This is comparably lower than the average age of women with breast cancer in the general population (64 years) but higher than the typical reduction mammaplasty patient.
12
The invasive carcinomas in our series showed favorable characteristics including small size and estrogen receptor/progesterone receptor positivity (Table III) . The tumor in patient 2 is more aggressive with lymph node metastasis, a higher nuclear grade, and HER2-neu receptor expression. Detection of cancer in these patients is optimized by a thorough preoperative work-up, communication between the surgeon and the pathologist regarding suspicious areas or biopsy sites, and thin sectioning of the gross specimen.
Standard preoperative work-up should start with a good history looking for predisposing factors and a personal or family history of breast cancer. Macromastia itself has been implicated as a predisposing factor based purely on the amount of breast tissue and thus potential foci for carcinogenesis. 13 This is supported by publications citing a decreased risk of cancer after reduction mammaplasty. Baasch et al. 13 reported a relative risk of 0.61 in 1240 Danish women treated surgically for breast hypertrophy, which is identical to the relative risk Brown et al.
14 reported in their cohort of Ontario women. This implies a role for reduction mammaplasty for cancer prevention, a complete reversal in thinking since Maliniac's presentation more than 40 years earlier.
The role of preoperative mammography is controversial. Few would dispute mammograms for patients over the age of 40 years, in accordance to the general guidelines of the American Cancer Society. 11 Should we obtain mammograms in women under age 40? In 1990, Perras 15 reviewed 1149 mammograms in patients over the age of 35 or with a positive family history who were undergoing cosmetic surgery of the breast. Cancer was detected primarily by mammogram in 34 patients; therefore, Perras's department has implemented a policy of mandatory preoperative mammograms before these procedures. Conversely, Snodgrass et al. 16 reviewed 208 patients under the age of 35 having nononcological breast surgery. Fifty-one had preoperative mammograms and none showed malignant changes. By chance, in our own series, all patients had mammograms before surgery and results of all of these scans were negative. Therefore, we cannot justify routine mammograms for those under the age of 40.
The pathologist has the great challenge of attempting to find a small clinically undetectable cancer in a large mass of breast tissue and fat. At our institution, routine pathological evaluation consists of thinly slicing the gross specimen and submitting a minimum of two blocks per breast plus any grossly abnormal tissue. Gross evaluation detected abnormal breast nodules in two of our patients and directed microscopic examination. The surgeon should discuss any suspicious nodularity or previous biopsy sites with the pathologist to further direct their efforts. If the patient is at high risk for cancer or has suspicious lesions on gross examination, specimen radiography may be utilized for further assistance in cancer localization. Ozmen et al. 17 used specimen radiography in 40 reduction mammaplasty specimens and found it to be easy and relatively inexpensive. There were no false-negative results in their study. Specimen radiography was utilized in one of our patients (patient 1) and detected clustered microcalcifications correlating with a pathological diagnosis of invasive tubular carcinoma. Caution must be exercised in interpreting results, however, as the piecemeal nature of resection distorts the breast architecture and could potentially disperse calcifications.
Breast cancer treatment in these patients follows the same oncological principles observed in the general population. As mentioned, observation is the current standard recommendation for lobular carcinoma in situ. These patients must be carefully observed, as they are at higher risk for developing future invasive malignancy.
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